Avalo Therapeutics Inc AVTX 深 沪
等待开盘 06-26 09:30:00 美东时间
18.01
-0.180
-0.99%
华盛通- 最 高18.69
- 今 开18.17
- 成交量 157.03万股
- 最 低 14.71
- 昨 收 18.19
- 总市值 203.51万
- 52周最高 24.27
- 市盈率 静 --
- 换手率 1389.63%
- 52周最低 4.61
- 委 比 -70.24%
- 总股本 0.00亿
- 历史最高 34.46
- 量 比 0.74
- 振 幅 21.88%
- 历史最低 0.02
- 每 手 1
- 风险率 4.12%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多This FormFactor Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday
Wall Street analysts upgraded EDU, MKTX, and FORM stocks. Check out their ratings on Benzinga's analyst ratings page before buying EDU.
06-12 21:06
Avalo Therapeutics Stock Soars After Positive LOTUS Trial Results
Avalo Therapeutics Inc (NASDAQ:AVTX) shares are surging after the company delivered a major clinical win, strengthened its balance sheet with a new offering and picked up fresh support from Wall Street analysts.
05-07 02:09
Avalo Therapeutics Stock Jumps 33% In Pre-Market Session: Here's Why
Avalo Therapeutics Inc. rises sharply in pre-market trading following a Phase 2 trial win and a $375 million offering.
05-06 16:44
BTIG Reiterates Buy on Avalo Therapeutics, Maintains $40 Price Target
BTIG analyst Julian Harrison reiterates Avalo Therapeutics (NASDAQ:AVTX) with a Buy and maintains $40 price target.
03-24 17:57
Earnings Scheduled For March 23, 2026
Companies Reporting Before The Bell • Avalo Therapeutics (NASDAQ:AVTX) is likel...
03-23 19:11
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
Avalo Therapeutics appoints Rita Jain, M.D., to its Board of Directors, enhancing its leadership in advancing AVTX-009, a Phase 2 anti-IL-1β antibody for hidradenitis suppurativa and other inflammatory diseases.
2025-06-18 11:00
AVITA Medical Highlights Largest Real-World Analysis Demonstrating Reduced Hospital Stay with RECELL
<p>Study highlights that AVITA Medical's RECELL technology reduces hospital stays and costs for burn patients, offering a more efficient and less painful alternative to traditional skin grafts.</p>
2025-06-09 13:00
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics announced that its management will participate in two investor conferences in June: the Jefferies Global Healthcare Conference on June 4 and the Oppenheimer Innovators in I&I Summit on June 25. The company focuses on treating immune dysregulation, with its lead asset being AVTX-009, an anti-IL-1β monoclonal antibody targeting inflammatory diseases.
2025-05-27 14:05
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) dipped 11.6% to $6.43. The company on Tuesday announced Phase 2 data for an investigational treatment for symptomatic Cerebral Cavernous Malformation (CCM). Nikola shares dipped 10.4% to $7.28 on Monday. Here are some other stocks moving in tod...
2024-09-04 01:41
Avalo Therapeutics 13G Filing Shows BVF Partners L.P. Reported a 9.99% Stake In The Co As Of August 13, 2024
Avalo Therapeutics 13G Filing Shows BVF Partners L.P. Reported a 9.99% Stake In The Co As Of August 13, 2024
2024-08-24 04:39
